Erratum

Article Outline

• Copyright

In the editorial entitled “Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?” (Auerbach, American Journal of Kidney Diseases 52:826-829, 2008), there were 2 numerical errors. In Table 1, ferumoxytol (AMAG Pharmaceuticals Inc, Cambridge, MA) is listed as having an iron concentration (mg/mL) of “50”, but should have been listed as having an iron concentration (mg/mL) of “30”. In the second full paragraph on page 827, tested doses for ferumoxytol were given as 255 mg and 510 mg; however, only the 510 mg amount was used. The full sentence in its corrected form follows: “The study by Singh and colleagues evaluated the safety, efficacy, and ease of administration of ferumoxytol, 510 mg, over 17 to 60 seconds in patients with CKD stages 1 to 5 and 5D.” These corrections do not change the conclusions of the editorial.